e.g. mhealth
Search Results (1 to 10 of 25 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 7 JMIR Cancer
- 4 JMIR Research Protocols
- 4 Journal of Medical Internet Research
- 3 JMIR Dermatology
- 3 JMIR Formative Research
- 3 JMIRx Med
- 1 JMIR Public Health and Surveillance
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Besides, immunotherapy-related adverse events (ir AEs) have been observed with the increasing frequency and duration of immunotherapy usage. Patients’ decisions to undergo immunotherapy are influenced by a range of factors, including their perceptions of its efficacy, side effects, procedural aspects, costs, their levels of knowledge about the treatment, and the comprehensiveness of advice provided by health care providers [5,6].
J Med Internet Res 2025;27:e60948
Download Citation: END BibTex RIS
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapies with BRAF/MEK inhibitors have significantly improved clinical outcomes for patients with melanoma and have become standard treatment for patients with high-risk and advanced disease [1-6]. Nevertheless, these novel systemic treatments are associated with short- and long-term (immune-related) adverse events (AEs) [7-10].
JMIR Cancer 2025;11:e58938
Download Citation: END BibTex RIS
We aimed to recruit three participant groups; individuals diagnosed with melanoma previously treated with immunotherapy, those with renal cell carcinoma previously treated with immunotherapy, and participants without direct experience with the targeted cancer types nor with immunotherapy (thus patients with other types of cancer or informal caregivers). For each participant group, our goal was to recruit seven to nine participants.
JMIR Form Res 2025;9:e57659
Download Citation: END BibTex RIS
Nevertheless, a substantial proportion of patients fail to benefit from immunotherapy, particularly those with lung cancer liver metastases [5]. The existence of baseline liver metastases in patients with lung cancer has been connected with a reduced response to immunotherapy.
JMIR Res Protoc 2024;13:e59152
Download Citation: END BibTex RIS
For advanced NSCLC without driver gene mutations, immunotherapy—specifically inhibitors targeting programmed death receptor 1 (PD-1) and its ligand (PD-L1)—has significantly improved patient outcomes. The 5-year overall survival rate has reached 20%, and even 40% in patients with high PD-L1 expression [9]. As a result, immunotherapy is recommended by the NCCN [2] as a standard first-line treatment for this type of lung cancer and has become a mainstream treatment option in clinical practice.
JMIR Res Protoc 2024;13:e64950
Download Citation: END BibTex RIS
Immune checkpoint blockers (ICBs) are immunotherapy drugs that enhance the immune system’s ability to target cancer by inhibiting specific pathways that regulate immune cell activity, such as programmed cell death protein 1, programmed death ligand 1, and cytotoxic T-lymphocyte–associated protein 4 [5]. These pathways are often exploited by cancer cells to evade immune detection.
JMIR Cancer 2024;10:e53443
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Female patients were significantly more likely to receive surgery than male patients (OR 1.27, 95% CI 1.06-1.53; P=.009), and male patients were significantly more likely to receive immunotherapy (OR 1.34, 95% CI 1.10-1.62; P=.003). There were no significant differences by sex for receiving radiation therapy (P=.84) or chemotherapy (P=.49).
JMIR Dermatol 2024;7:e56684
Download Citation: END BibTex RIS
Tumor immunotherapy is an innovative treatment today. After the implementation of China's new medical insurance rates in 2022, the monthly treatment cost of immunotherapy has entered the “thousand era,” which greatly improves the accessibility of drugs. However, tumor immunotherapy has obvious uncertainty and complexity [1]. Accurate transmission of immunotherapy information to the population is important to the survival and quality of life of patients with cancer [2].
JMIR Form Res 2024;8:e50561
Download Citation: END BibTex RIS
In recent years, the introduction of immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the clinical outcome of patients with melanoma and has become the standard of care [1-4]. However, treatment with ICIs is associated with short- and long-term immune-related adverse events (AEs) [5-7], most commonly fatigue [7,8], and a deteriorated health-related quality of life (HRQo L) [6,9,10].
JMIR Res Protoc 2023;12:e49252
Download Citation: END BibTex RIS